<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt and Burkitt-like <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are rapidly growing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> which require specialized therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Although intensive, multi-agent regimens have been effective in children, results are more variable in adults </plain></SENT>
<SENT sid="2" pm="."><plain>Magrath et al. previously described a regimen that was highly effective in children and young adults </plain></SENT>
<SENT sid="3" pm="."><plain>This phase II study of a modified Magrath regimen was designed to assess its efficacy in older adults and reduce treatment-related toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>Fourteen patients with Burkitt/Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and median age of 47 years were stratified into two categories: low-risk (<z:mpath ids='MPATH_458'>normal</z:mpath> LDH and a single focus of disease measuring less than 10 cm, 3 patients) and high risk (<z:hpo ids='HP_0000001'>all</z:hpo> other, 11 patients) </plain></SENT>
<SENT sid="5" pm="."><plain>Low-risk patients received three cycles of modified CODOX-M (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, adriamycin, <z:chebi fb="0" ids="28445">vincristine</z:chebi> with intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> followed by high-dose systemic <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, regimen A) </plain></SENT>
<SENT sid="6" pm="."><plain>High-risk patients received four alternating cycles of regimens A and B (A-B-A-B) </plain></SENT>
<SENT sid="7" pm="."><plain>Regimen B consisted of ifosfamide, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi> and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (IVAC) </plain></SENT>
<SENT sid="8" pm="."><plain>The modified treatment regimen was associated with no grade 3/4 neuropathy and only one episode of grade 3/4 mucositis </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients completed protocol therapy and there were no treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Twelve patients (86%, 90% CI: 61 97%) achieved a complete response; 1 patient achieved a PR and 1 patient died of progressive disease </plain></SENT>
<SENT sid="11" pm="."><plain>Nine patients (64%) are alive and disease free at a median follow-up of 29 months </plain></SENT>
<SENT sid="12" pm="."><plain>This modified Magrath regimen is effective and well-tolerated in a representative group of older adult patients </plain></SENT>
</text></document>